Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [25]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10159-2-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10159-2-AP, RRID:AB_2266881
- Product name
- MYCN antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated MYCN antibody (Cat. #10159-2-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Ferroptosis-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma: A multi-cohort retrospective study.
7,7"-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma.
Amplification of Extrachromosomal MYC Paralogs Shapes Immunosuppressive Tumor Microenvironment in Small Cell Lung Cancer.
CARM1-induced lncRNA NEAT1 synchronously activates MYCN and GalNAcT-I to accelerate the progression of neuroblastoma.
TNFSF14-HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ-Induced Psoriatic Skin Inflammation via Activating NF-κB/TWIST1 Signalling Pathway.
Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11.
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.
High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma.
Fusobacterium necrophorum Promotes Apoptosis and Inflammatory Cytokine Production Through the Activation of NF-κB and Death Receptor Signaling Pathways.
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance.
Divergent transcriptional regulation of astrocyte reactivity across disorders.
Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin-induced apoptosis in epithelial ovarian cancer.
Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients.
An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes.
Comparative proteomics reveals Cryptosporidium parvum manipulation of the host cell molecular expression and immune response.
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma.
Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.
Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[(18)F]FGln PET Imaging.
Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Li L, Pang J, Chen J, Pan Y, Liang L, Bai X, He Y, Yang H
Medicine 2026 Jan 23;105(4):e47262
Medicine 2026 Jan 23;105(4):e47262
7,7"-dimethoxyagastisflavone induced MYCN/MYBL2-dependent apoptosis and metabolism reprogramming in Sonic Hedgehog medulloblastoma.
Wu YS, Lin HH, Wu KS, Huang YT, Liao JY, Chu SS, Wong TT, Hsieh CL, Chang CC, Sung SY, Lin CY, Lin YL
Journal of translational medicine 2026 Feb 12;24(1)
Journal of translational medicine 2026 Feb 12;24(1)
Amplification of Extrachromosomal MYC Paralogs Shapes Immunosuppressive Tumor Microenvironment in Small Cell Lung Cancer.
Zhang J, Jin Y, Lin H, Deng J, Ju Y, Hu X, She J, Liang Z, Dai K, Qiu M, Sun K, Wang J, Yang F, Chen J, Yang E, Li X
Clinical cancer research : an official journal of the American Association for Cancer Research 2025 Nov 3;31(21):4529-4542
Clinical cancer research : an official journal of the American Association for Cancer Research 2025 Nov 3;31(21):4529-4542
CARM1-induced lncRNA NEAT1 synchronously activates MYCN and GalNAcT-I to accelerate the progression of neuroblastoma.
Hu Z, Xu W, Wang H, Li M, Wang J, Sun C, Yang X
Gene 2025 Feb 20;938:149164
Gene 2025 Feb 20;938:149164
TNFSF14-HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ-Induced Psoriatic Skin Inflammation via Activating NF-κB/TWIST1 Signalling Pathway.
Long SJ, Zheng QY, Xu F, Li GQ, Chen J, Chen WJ, Xu JM, Gao XL, Liang SJ, Xu GL
Journal of cellular and molecular medicine 2025 Aug;29(15):e70774
Journal of cellular and molecular medicine 2025 Aug;29(15):e70774
Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11.
Mlakar V, Oehme I, Lesne L, Najafi S, Ansari M, Gumy-Pause F
Frontiers in oncology 2024;14:1433256
Frontiers in oncology 2024;14:1433256
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.
Murray JE, Valli E, Milazzo G, Mayoh C, Gifford AJ, Fletcher JI, Xue C, Jayatilleke N, Salehzadeh F, Gamble LD, Rouaen JRC, Carter DR, Forgham H, Sekyere EO, Keating J, Eden G, Allan S, Alfred S, Kusuma FK, Clark A, Webber H, Russell AJ, de Weck A, Kile BT, Santulli M, De Rosa P, Fleuren EDG, Gao W, Wilkinson-White L, Low JKK, Mackay JP, Marshall GM, Hilton DJ, Giorgi FM, Koster J, Perini G, Haber M, Norris MD
Nature communications 2024 Jul 11;15(1):5585
Nature communications 2024 Jul 11;15(1):5585
High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma.
Ogushi K, Yokobori T, Nobusawa S, Shirakura T, Hirato J, Erkhem-Ochir B, Okami H, Dorjkhorloo G, Nishi A, Suzuki M, Otake S, Saeki H, Shirabe K
Cancers 2023 Sep 8;15(18)
Cancers 2023 Sep 8;15(18)
Fusobacterium necrophorum Promotes Apoptosis and Inflammatory Cytokine Production Through the Activation of NF-κB and Death Receptor Signaling Pathways.
Wang FF, Zhao PY, He XJ, Jiang K, Wang TS, Xiao JW, Sun DB, Guo DH
Frontiers in cellular and infection microbiology 2022;12:827750
Frontiers in cellular and infection microbiology 2022;12:827750
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance.
Mañas A, Aaltonen K, Andersson N, Hansson K, Adamska A, Seger A, Yasui H, van den Bos H, Radke K, Esfandyari J, Bhave MS, Karlsson J, Spierings D, Foijer F, Gisselsson D, Bexell D
Science advances 2022 Oct 28;8(43):eabq4617
Science advances 2022 Oct 28;8(43):eabq4617
Divergent transcriptional regulation of astrocyte reactivity across disorders.
Burda JE, O'Shea TM, Ao Y, Suresh KB, Wang S, Bernstein AM, Chandra A, Deverasetty S, Kawaguchi R, Kim JH, McCallum S, Rogers A, Wahane S, Sofroniew MV
Nature 2022 Jun;606(7914):557-564
Nature 2022 Jun;606(7914):557-564
Low expression of MYCN promotes cisplatin resistance by suppressing cisplatin-induced apoptosis in epithelial ovarian cancer.
Yu R, Zhang H, Wang R, Xiao L
Oncology letters 2022 Dec;24(6):423
Oncology letters 2022 Dec;24(6):423
Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients.
Jung M, Kowalczyk K, Hankins R, Bandi G, Kallakury B, Carrasquilla MA, Banerjee PP, Grindrod S, Dritschilo A
Cancer research communications 2022 Dec;2(12):1617-1625
Cancer research communications 2022 Dec;2(12):1617-1625
An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes.
Fan Z, Kong M, Miao X, Guo Y, Ren H, Wang J, Wang S, Tang N, Shang L, Zhu Z, Liu H, Zhu W, Shi X
Frontiers in cell and developmental biology 2021;9:742319
Frontiers in cell and developmental biology 2021;9:742319
Comparative proteomics reveals Cryptosporidium parvum manipulation of the host cell molecular expression and immune response.
Li T, Liu H, Jiang N, Wang Y, Wang Y, Zhang J, Shen Y, Cao J
PLoS neglected tropical diseases 2021 Nov;15(11):e0009949
PLoS neglected tropical diseases 2021 Nov;15(11):e0009949
A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma.
Gifford AJ, Murray J, Fletcher JI, Marshall GM, Norris MD, Haber M
Current protocols 2021 Nov;1(11):e310
Current protocols 2021 Nov;1(11):e310
Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.
Szemes M, Melegh Z, Bellamy J, Park JH, Chen B, Greenhough A, Catchpoole D, Malik K
Cancers 2021 Feb 6;13(4)
Cancers 2021 Feb 6;13(4)
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, Groth J, Foo WC, Liang C, Hu H, Huang J
Molecular cancer 2019 Jan 18;18(1):11
Molecular cancer 2019 Jan 18;18(1):11
Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.
Lee YJ, Chang WW, Chang CP, Liu TY, Chuang CY, Qian K, Zheng YG, Li C
Scientific reports 2019 Feb 11;9(1):1771
Scientific reports 2019 Feb 11;9(1):1771
Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[(18)F]FGln PET Imaging.
Li C, Huang S, Guo J, Wang C, Huang Z, Huang R, Liu L, Liang S, Wang H
Molecular imaging and biology 2019 Dec;21(6):1117-1126
Molecular imaging and biology 2019 Dec;21(6):1117-1126
Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.
DeVore SB, Young CH, Li G, Sundararajan A, Ramaraj T, Mudge J, Schilkey F, Muth A, Thompson PR, Cherrington BD
Molecular and cellular biology 2018 Oct 1;38(19)
Molecular and cellular biology 2018 Oct 1;38(19)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.
Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F
eLife 2017 Apr 20;6
eLife 2017 Apr 20;6
Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.
Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC
Frontiers in oncology 2015;5:111
Frontiers in oncology 2015;5:111
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H
Cancer 2013 Oct 15;119(20):3718-26
Cancer 2013 Oct 15;119(20):3718-26
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H
Pediatric blood & cancer 2013 Mar;60(3):363-70
Pediatric blood & cancer 2013 Mar;60(3):363-70
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The MYCN antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human MYCN. This antibody recognizes human, mouse, rat antigen. The MYCN antibody has been validated for the following applications: ELISA, WB analysis.
